Irving
IRVING, Texas and ABBOTT PARK, Illinois, June 24, 2011 -
− Reata
Pharmaceuticals, Inc.
IRVING, Texas and ABBOTT PARK, Illinois, June 16, 2011 -
- Pivotal clinical trial
will further assess drug candidate's effect on kidney function
-
Reata
Pharmaceuticals, Inc.
IRVING, Texas and ABBOTT PARK, Illinois, November 20, 2010 - Reata Pharmaceuticals and Abbott (NYSE: ABT) today announced data from a
Phase 2b study which suggests that bardoxolone methyl, an investigational
treatment for chronic kidney disease (CKD), may reduce the stage of CKD and
improve estimated glomerular filtration rate (eGFR) and other measures of
kidney function in the majority of patients receiving the drug.
